中美同步开发赞布替尼。
Simultaneous development of zanubrutinib in the USA and China.
机构信息
Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, China.
Office of Clinical Trial Institute, Beijing Tsinghua Changguang Hospital, Beijing, China.
出版信息
Nat Rev Clin Oncol. 2020 Oct;17(10):589-590. doi: 10.1038/s41571-020-0414-y.
Abstract
Zanubrutinib was recently granted expedited approval by the USA and Chinese drug regulatory authorities for the treatment of mantle cell lymphoma, thus becoming the first investigational new drug discovered in China to achieve simultaneous development in both countries. Here, we provide an overview of the regulatory processes and considerations of the two health authorities and discuss the pathways of concurrent review and approval.
摘要
赞布替尼最近获得美国和中国药品监管机构的加速批准，用于治疗套细胞淋巴瘤，成为中国首个同时在两国开发的新药。本文概述了中美两国监管机构的监管流程和考量因素，并讨论了同步审查和批准的途径。
相似文献
1
Simultaneous development of zanubrutinib in the USA and China.中美同步开发赞布替尼。
Nat Rev Clin Oncol. 2020 Oct;17(10):589-590. doi: 10.1038/s41571-020-0414-y.
2
Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.泽布替尼：一种用于治疗复发/难治性套细胞淋巴瘤的新型布鲁顿酪氨酸激酶抑制剂。
Drugs Today (Barc). 2020 Aug;56(8):531-539. doi: 10.1358/dot.2020.56.8.3158047.
3
Ibrutinib approved for mantle cell lymphoma.依鲁替尼获批用于套细胞淋巴瘤。
Cancer Discov. 2014 Jan;4(1):OF1. doi: 10.1158/2159-8290.CD-NB2013-172. Epub 2013 Dec 12.
4
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.一项在不适合移植、未经治疗的套细胞淋巴瘤患者中比较泽布替尼联合利妥昔单抗与苯达莫司汀联合利妥昔单抗的 III 期研究。
Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28.
5
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.目前布鲁顿酪氨酸激酶抑制剂在治疗套细胞淋巴瘤中的作用和新出现的证据。
Hematol Oncol Clin North Am. 2020 Oct;34(5):903-921. doi: 10.1016/j.hoc.2020.06.007. Epub 2020 Aug 1.
6
Zanubrutinib: First Approval.赞布替尼：首次批准。
Drugs. 2020 Jan;80(1):91-97. doi: 10.1007/s40265-019-01252-4.
7
Ibrutinib approved for the treatment of mantle cell lymphoma.伊布替尼获批用于治疗套细胞淋巴瘤。
Clin Adv Hematol Oncol. 2013 Dec;11(12):808.
8
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼和泽布替尼对套细胞淋巴瘤患者自然杀伤（NK）细胞效应功能的不同影响
Haematologica. 2020 Jan 31;105(2):e76-e79. doi: 10.3324/haematol.2019.220590. Print 2020.
9
Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.从淋巴瘤的磷脂酰肌醇 3-激酶抑制剂中学习——走向更少但更好的模式。
Br J Haematol. 2024 May;204(5):1582-1584. doi: 10.1111/bjh.19456. Epub 2024 Apr 6.
10
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.FDA 批准：依鲁替尼用于既往治疗过的套细胞淋巴瘤和既往治疗过的慢性淋巴细胞白血病患者。
Clin Cancer Res. 2015 Aug 15;21(16):3586-90. doi: 10.1158/1078-0432.CCR-14-2225.
引用本文的文献
1
Cancer Drugs Approved Based on Surrogate Endpoint: A Retrospective Observational Study in the United States and China.基于替代终点获批的抗癌药物：一项在美国和中国开展的回顾性观察研究
Cancer Med. 2025 Apr;14(8):e70864. doi: 10.1002/cam4.70864.
2
New Drug Approvals in China: An International Comparative Analysis, 2019-2023.《中国新药获批情况：2019 - 2023年国际比较分析》
Drug Des Devel Ther. 2025 Apr 3;19:2629-2639. doi: 10.2147/DDDT.S514132. eCollection 2025.
3
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.布鲁顿酪氨酸激酶抑制剂治疗B细胞恶性肿瘤中国专家共识
Exp Hematol Oncol. 2023 Oct 16;12(1):92. doi: 10.1186/s40164-023-00448-5.
4
Highly enantioselective Rh-catalyzed asymmetric reductive dearomatization of multi-nitrogen polycyclic pyrazolo[1,5-]pyrimidines.铑催化多氮多环吡唑并[1,5 - ]嘧啶的高度对映选择性不对称还原脱芳构化反应
Chem Sci. 2023 Jul 28;14(34):9048-9054. doi: 10.1039/d3sc02086j. eCollection 2023 Aug 30.
5
Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China.2010年至2021年中国进口罕见病药物的市场趋势与审批滞后分析
Ther Innov Regul Sci. 2023 Nov;57(6):1314-1321. doi: 10.1007/s43441-023-00572-8. Epub 2023 Aug 31.
6
Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability and .具有优化生物利用度的靶向布鲁顿酪氨酸激酶（BTK）的蛋白质靶向嵌合体（PROTAC）的设计、合成及评估
RSC Med Chem. 2023 Jun 21;14(8):1562-1566. doi: 10.1039/d3md00216k. eCollection 2023 Aug 16.
7
Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.药物重定位靶向 KRAS G12C 突变：一项机器学习、分子对接和分子动力学研究。
Int J Mol Sci. 2022 Dec 30;24(1):669. doi: 10.3390/ijms24010669.
8
Evolution of drug regulations and regulatory innovation for anticancer drugs in China.中国抗癌药物法规的演变与监管创新
Acta Pharm Sin B. 2022 Dec;12(12):4365-4377. doi: 10.1016/j.apsb.2022.08.004. Epub 2022 Aug 13.
9
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology.对恶性胸膜间皮瘤提出的新治疗方法的分析引发了人们对肿瘤学临床试验实施的担忧。
J Transl Med. 2022 Dec 13;20(1):593. doi: 10.1186/s12967-022-03744-6.
10
Zanubrutinib in lymphoproliferative disorders: a comprehensive review.泽布替尼治疗淋巴增殖性疾病：全面综述
Ther Adv Hematol. 2022 May 27;13:20406207221093980. doi: 10.1177/20406207221093980. eCollection 2022.
Zotero 插件